Pure Global
NCT06414798

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants.

A First-in-Human Single Ascending Dose and Mass Balance Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 in Healthy Adult Subjects
AbbVie·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Healthy Volunteers
Drug/Device/Intervention
Drug: ABBV-1088
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
AbbVie
Location
Grayslake, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
May 13, 2024
End date
Nov 28, 2024
Enrollment
48 participants
Primary outcome

Maximum Plasma Concentration (Cmax) of ABBV-1088,Time to Cmax (Tmax) of ABBV-1088,Terminal Phase Elimination Rate Constant (Beta) of ABBV-1088,Terminal Phase Elimination Half-Life (t1/2) of ABBV-1088,Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-1088,Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-1088,Number of Participants With Adverse Events (AEs)

Summary

This study will assess the single dose safety, tolerability and pharmacokinetic properties of
 ABBV-1088 in healthy adult participants

ICD-10 classifications
Healthy person accompanying sick personRoutine general health check-up of armed forcesRoutine general health check-up of sports teamsRoutine general health check-up of inhabitants of institutions
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06414798
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06414798 through Pure Global AI's free database. This Phase 1 trial is sponsored by AbbVie and is currently Not yet recruiting. The study focuses on Healthy Volunteers. Target enrollment is 48 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.